Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line by unknown
BriefDefinitive Report
GENETIC ANALYSIS OF THE HUMAN TUMOR NECROSIS
FACTOR a/CACHECTIN PROMOTER REGION IN A
MACROPHAGE CELL LINE
BYJAMES S. ECONOMOU,* KRISTINA RHOADES,* RICHARD ESSNER,*
WILLIAM H. McBRIDE,$ JUDITH C. GASSON,4 AND DONALD L. MORTON*
From the *Division of Surgical Oncology, John Wayne Cancer Clinic, Armand Hammer
Laboratories; and the $Department ofRadiation Oncology and the DDvvssion of
Hematology-Oncology, Centerfor the Health Sciences,
University of California, Los Angeles, California 90024
TNFce/cachectin is an important immunoregulatory cytokine with a broad range
of biological properties (1-3). These include cytotoxicity for tumor cells (4), aug-
mentation ofhumoral and cellular immunity (5, 6), and activation ofmacrophages
(7) and neutrophils (8). TNF has been implicated as aproximal mediator ofGram-
negative endotoxemia (9) and circumstantially in the toxicity of IL-2-based im-
munotherapy regimens (10).
Although predominantly a product ofmononuclear phagocytes, TNF/cachectin
is also produced by T cells, B cells, and NK cells (11-13). A number of cytokines
and bacterial products can induce TNFa/cachectin production; phorbol esters (PMA)
are strong agonist signals (14).
Little is known about regulation of TNF/cachectin gene expression at the level
oftranscription. Murine TNFtranscription can be induced by inhibition ofprotein
synthesis implicating atranscriptional repressor(15). However, no promoter region
studies are available. In this report, we describe genetic studies using recombinant
constructs containing thehumanTNFa/cachectin promoter linked to theluciferase
(Luc) reporter gene in a transienttransfection system (16). TNF/cachectinpromoter
constructions were inducible by PMA in the U937 macrophage cell line.
Materials and Methods
Reagents.
￿
RPMI 1640, FCS, and antibiotics were obtained from Flow Laboratories, Inc.,
McLean, VA. PMA, ATP, and firefly luciferase were purchased from Sigma Chemical Co.,
St. Louis, MO. D-luciferin was purchasedfrom Analytical Luminescence Laboratorires, San
Diego, CA. The promoterless luciferase plamids, pXP 1 and 2, used in this work were the
generous gift ofDr. S. Nordeen, University ofColorado (17). TheTNFa/cachectin genomic
clone (2) was the generous gift of Dr. Michael Shepard of the Genentech Corporation, So.
San Franscisco, CA.
Cell Lines.
￿
TheU937 humanmacrophage cell line wasobtained from the American Type
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Culture Collection, Rockville, MD, and passaged in RPMI 1640, 10% FCS, and antibiotics.
Cells were split the day before transfection.
Transfection.
￿
Cells were transfected using the technique of electroporation essentially as
described by Cann et al. (18). Cells were resuspended in RPMI 1640 + 20% FCS at 5 x
106 in 0.25 ml, to which 25 Wg plasmid DNA was added. Electroporation was performed with
a single pulse from a Gene Pulser apparatus (Bio-Rad Laboratories, Richmond, CA) with
a capacitance extender unit (250 V, 960 ttFd). Cells were incubated on ice for at least 10 min
before and afterelectroporation and then resuspended in 4 ml RPMI 1640 + 10% FCS in
6-well plates (Costar, Cambridge, MA). The decay constant for these electroporations was
generally between 45 and 55 ms. Cell viability immediately after electroporation averaged
50-60%.
Luciferase Assay.
￿
Transfected cells were retrieved with a plastic policeman after 24 h of
culture, washed, and resuspended in 100 it]lysisbuffer (17). Cells were lysed by three freeze-
thaw cycles and the cellular debris was sedimented in a microfuge. 10-25 /Al of supernatant
was assayed for luciferase according to de Wet et al. (16) using a luminometer (Dupont Co.,
Wilmington, DE). The luminometer records data as relative light units (peak), which is directly
proportional to luciferase concentration over a 7-log range. This instrument is sensitive to
the level of 10-7 to 10-8 U of firefly luciferase. Protein concentration of extracts was mea-
sured using the Coomassie Blue G250 binding assay (Bio-Rad Laboratories) with BSA as
a standard, and generally averaged 15-20 Ug/106 cells.
Plasmid Construction.
￿
The techniques described were performed essentially as described
by Maniatis et al. (19). The TNF promoter region, a 705-bp Aha II/Eco RI fragment, was
excised from the human TNFa gene (which had been cloned into pUCl3pML and supplied
by Genentech, So. San Francisco, CA) and blunt-end ligated into the multiple cloning site
of pUC18 at the Barn HI site. This fragment was then excised with Hind III and Kpn I and
ligated downstream from the luciferase gene contained in pXPI and pXP2. The plasmids
pXP1 and pXP2 contain opposite orientations of a multiple cloning site, thus allowing inser-
tion of the TNF promoter in forward and reverse orientations. Unidirectional deletions were
then made in the forward orientation promoterusing exonuclease III, as described by Heinkoff
(20). Briefly, the plasmid containing the TNF promoter in the forward orientationjust down-
stream of the luciferase gene, pTNF (-615) Luc, was digested with Hind III and the over-
hangs were filled in with thionucleotides to protect the ends from digestion with exonuclease
III. The plasmid was then digested with Sal I to expose a 5' overhang just 5' of the TNF
promoter, which would be susceptible to digestion with Exo III and allow digestion into the
promoter region. The Exo III digest was performed at 37°C and samples were taken at 30-s
intervals for 10 min. All samples were S1 nuclease treated to blunt end and then religated.
To determine the extent ofdeletion into the 5' end ofthe promoter, each mutant was sequenced
as described by Maxam and Gilbert (21). Briefly, each deleted promoter was labeled at the
5' end at the Bam HI site and digested again with Sst I or Dde I, depending on the extent
of the deletion, to leave a single end-labeled probe.
Results and Discussion
The putative TNFa/cachectin promoter region was isolated from the 5' flanking
region ofthe genomic clone with Eco RI/Aha II, which yielded a 705-bp fragment,
615 by ofwhich are upstream from the transcription start site (TSS position 0). The
Aha II site is upstream from the initiation codon. This flanking region was ligated
into the luciferase (Luc) reporter gene in the forward (pTNF [ -615]Luc) and reverse
(pTNF [+615]Luc) orientations. A series of 5' truncations of pTNF (-615)Luc was
generated by unidirectional exonuclease III digestion, which produced promoter
region constructs ranging in length from -615 to -36 by upstream from the TSS.
These constructs were transfected into the U937 cell line using electroporation.
Transfected cellswere cultured for 24 h in the presence or absence of 10 ng/ml PMA,
washed, lysed, and assayed for Luc using a luminometer. The Luc reporter geneECONOMOU ET AL.
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TABLE I
Induction of Full-length TNF-a Promoter Construct by
Phorbol Ester in U937 Cells
U937 cells were transfected with indicated plasmid and cultured in the presence or absence
of PMA. Cells were harvested and assayed for Luciferase as described in Materials and Methods.
Luciferase concentration is expressed as relative light units (per 106 transfected cells). The in-
dex of PMA induction of construct pTNF( - 615)Luc is expressed in parentheses. Replicate
luciferasc assays arc reproducible to within 7-10% .
under control ofthe CMV viral promoter served as a positive transfection control.
Thereissome variabilityin the transfectionefficiency ofthesecells from experiment
toexperiment with better responses achieved in freshly split log phase cells andwith
the appropriate electroporationdecay constant. As previously noted by others (17),
the promoterless Luc plasmid (pXP) has very weak cryptic promoter activity. The
TNFa/cachectin promoterin the reverse orientation (pTNF[+615]Luc) is inactive.
In the forward orientation, the full-length promoter construct had either weak or
absent basal (uninduced) activity in U937 cells. PMA caused amean 12-fold induc-
tion (range, 3.2-33) of the full-length TNF promoter construct (see Table I). The
series of 5' promoter truncations were studied (Fig. 1). Marked induction of pro-
moter activity was observed when transfected cells were activated with PMA, espe-
cially with some ofthe shorter constructs. PMA-inducible promoter activity is still
retained in constructs with only 95 bp, but not 36 bp, upstream from TSS. The
U937 cell line generally does not constitutively produce TNF mRNA or protein,
but PMA will induce TNF mRNA with peak expression at 4 h and release 0.5 U
TNF/106 cells (data not shown; reference 2). These results demonstrate PMA-in-
ducible promoter/enhancer activity in the 5' flanking region of the human TNF
cx/cachectin gene.
Analysis ofthe TNF promoter region (Fig. 2) reveals a cAMP-responsive element
FIGURE 1.
￿
Activity ofTNF/cachectin
promoter region constructs in unin-
duced and PMA-induced U937 cells.
Cells were transfected with 25,ugof in-
dicated plasmid and cultured for 24 h
in the presence or absence of 10 ng/ml
PMA. Cells were then washed, 1ysed,
and assayed for Luciferase. Results are
expressed as relative light units per 106
transfected cells. The data presented
are reproducible in replicate assays to
within 7-10%. Thispattern ofconstruct
induction is represenative of five ex-
periments with U937 cells.
Plasmid
Induction
signal 1
Luciferase concentration in experiments:
2 3 4 5 6
CMV-Luc 20,800 17,600 33,800 683,000 151,000 1,030,000
pXP 440 40 30 370 100 730
pXP PMA 40 30 0 0 60 250
pTNF(- 615)Luc 770 30 470 4,190 400 1,400
pTNF(-615)Luc PMA 5,900 910 4,830 19,900 1,280 16,600
Fold induction (7 .6) (33) (10.2) (4.7) (3.2) (11 .8)
PLASMID RELATIVE LIGHT
UNITS
Uninduced PMA-induced
Luc
CMV-Luc -~ 21,500 20,000
pXP 40 30
pTNF("615)Luc ~ 40 40
pTNF(-615)Luc 30 930
pTNF(-526)Luc -- 70 5,100
pTNF(-479)Luc ~~ 240 5,900
pTNF(-295)Luc 110 2290
PTNF(-120)Luc -+~ 60 2,640
pTNF(-95)Luc "~ 160 5.400
pTNF(-36)Luc --~ 30 60324
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AP-2
homology
GGC CC ACTAC
-130
to lymphotoxin
￿
Cae
￿
FIGURE 2.
￿
Sequence of human TNF-a
GCTT CCT G AGATG AGCTC
￿
GGG TTTCT CCACC AAGGA
￿
promoter region. The 130-bp region up-
-1
￿
-110
￿
-100
￿
-90 stream from transcription start site (TSS)
is shownwith putative cis-acting sequence
SP-1
￿
motifs identified by boxes. The TATAA
AGTTT TCCGC TGGTT GAATG ATTCT TTCCC CGCCCI TCCTC
￿
box is underlined.
-90
￿
-70
￿
-60
TSS"
TCGC CCAGG GAFAT ATAAA GGCAG TTGTT GGCAC ACCCA
-40
￿
-30
￿
-20
￿
-10
(CRE)at positions -107 to -99 byupstream fromthe TSS. The CRE is reportedly
not responsive to phorbol esters (22), consistent with our findings of PMA induc-
ibility in construct pTNF (-95)Luc, in which this enhancer element is eliminated.
An AP-2 consensus sequence is present atposition -36 to -28 (23). AP-2 is respon-
sive to phorbol esters and cAMP, apparently through different signal-transduction
pathways.
An AP-1 sequence is present at position -66 to -60 and is also responsive to
phorbol esters. AP-1 and/or AP-2 mayberesponsibleforinducibility. When the TNFa
and TNF0 (lymphotoxin) promoters are compared, there is a 15-bp sequence of
exact homology (112-127 by upstream from the TSS in the TNFa gene) without
recognizablesimilarity to known promoter/enhancermotifs (24). Thissequencewould
also not appear to play a role in PMA induction ofthe TNFa promoter. DNase
I footprinting analysis and site-directed mutagenesis will be required to correlate
these geneticdata with the interaction oftrans-acting factors with this promoter region.
Summary
The 615-bp 5' flanking region ofthe human TNFa/cachectin gene was isolated
and ligated to the luciferase reporter gene. In addition, a series oftruncated pro-
moter constructswasgenerated by exonuclease III digestion. The promoter activity
of these constructs was studied in a transient transfection system using the TNF
a-producingU937 cell line. Full-lengthand truncated TNF promoter constructions
extending from -615 to -95 by relative to the transcription start site (TSS) could
be induced by phorbol esters. A construct truncated to within 36 by of the TSS
(andwithin 11 by ofthe TATAAbox) wasinactive. Therefore, thephorbolester respon-
sive is localized in the TNF/cachectin promoter to a relatively short region proximal
to the TATAA box.
The valuable advice ofA. Cann, S. Nimer, and S. Golub is acknowledged as isthe technical
assistance of S. Kallaos.
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